1. Academic Validation
  2. Regulation of cardiac gene expression by KLF15, a repressor of myocardin activity

Regulation of cardiac gene expression by KLF15, a repressor of myocardin activity

  • J Biol Chem. 2010 Aug 27;285(35):27449-27456. doi: 10.1074/jbc.M110.107292.
Joost J Leenders 1 Wino J Wijnen 1 Monika Hiller 1 Ingeborg van der Made 1 Viola Lentink 2 Rick E W van Leeuwen 2 Veronica Herias 2 Saraswati Pokharel 3 Stephane Heymans 2 Leon J de Windt 2 Morten A Høydal 4 Yigal M Pinto 1 Esther E Creemers 5
Affiliations

Affiliations

  • 1 Heart Failure Research Center, Academic Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
  • 2 Experimental and Molecular Cardiology, Cardiovascular Research Institute Maastricht, University of Maastricht, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands.
  • 3 Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, Kentucky 40292.
  • 4 Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, NO-7491 Trondheim, Norway.
  • 5 Heart Failure Research Center, Academic Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. Electronic address: [email protected].
Abstract

Pathological forms of left ventricular hypertrophy (LVH) often progress to heart failure. Specific transcription factors have been identified that activate the gene program to induce pathological forms of LVH. It is likely that apart from activating transcriptional inducers of LVH, constitutive transcriptional repressors need to be removed during the development of cardiac hypertrophy. Here, we report that the constitutive presence of Krüppel-like factor 15 (KLF15) is lost in pathological hypertrophy and that this loss precedes progression toward heart failure. We show that transforming growth factor-beta-mediated activation of p38 MAPK is necessary and sufficient to decrease KLF15 expression. We further show that KLF15 robustly inhibits myocardin, a potent transcriptional activator. Loss of KLF15 during pathological LVH relieves the inhibitory effects on myocardin and stimulates the expression of serum response factor target genes, such as atrial natriuretic factor. This uncovers a novel mechanism where activated p38 MAPK decreases KLF15, an important constitutive transcriptional repressor whose removal seems a vital step to allow the induction of pathological LVH.

Figures
Products